Normal individuals express the two alternative transcripts, FMR2 and Ox19, from the FRAXE-associated CpG island. Molecular analysis of the Ox19 transcript suggests that it is a truncated isoform of the FMR2 gene with an alternative 3′ end. Both isoforms showed a similar pattern of expression, with the Ox19 isoform expressed at a much lower level. Fibroblasts, chorionic villi and hair roots showed the highest level of FMR2 expression, whole blood cells and amniocytes showed very low expression, and the transcript was not detected in lymphoblasts. Fibroblasts of 11 individuals from seven families segregating FRAXE were assayed for FMR2 expression and FRAXE CpG island methylation. A man with an unmethylated expansion of 0.6 kb expressed FMR2 and represents a pre-mutation carrier. All chromosomes with FRAXE CCG expansions of 0.8 kb or greater were fully methylated and did not express the FMR2 gene, analogous to the mechanism of silencing the FMR1 gene in carriers of the FRAXA full mutation. The boundary between FRAXE pre-mutation and FRAXE full mutation is between 0.7 and 0.8 kb. Two men with absence of FMR2 expression in fibroblasts were not mentally impaired, suggesting that IQ in some men with FRAXE full mutation may remain within the normal range. Although molecular tools to study FRAXE non-specific mental retardation are now available, further psychometric and molecular studies are needed to characterize the effect of the FRAXE full mutation for the purpose of genetic counselling.
INTRODUCTION
FRAXE is a folate-sensitive fragile site in Xq28 ∼600 kb distal to the FRAXA (1,2). Molecular characterization revealed that individuals expressing FRAXE had amplifications of a CCG repeat adjacent to a CpG island (3) . Normal individuals showed 4-39 (3-5) copies of the polymorphic FRAXE CCG repeat, while individuals expressing the fragile site had >200 copies and their CpG island was fully methylated (3) . These findings were similar to those found for another cloned folate-sensitive fragile site FRAXA (6) (7) (8) .
In the first family reported with FRAXE (1,9), the fragile site was not clearly segregating with mental retardation (MR). Further studies on additional families co-segregating mental impairment and the FRAXE fragile site suggested that an aetiological relationship may exist between FRAXE and mild non-specific X-linked mental retardation (XLMR) (9) (10) (11) (12) . This relationship was difficult to establish in the absence of a phenotype other than mild (or borderline) non-specific MR or a gene associated with FRAXE. Recently, the gene FMR2 associated with the FRAXE fragile site was cloned (13, 14) . This was accomplished by positional cloning of a candidate FRAXE gene interrupted by two overlapping submicroscopical deletions in Xq28 (15) and a large-scale sequencing approach (14) . FMR2 was confirmed as the FRAXE-associated gene when cytogenetically positive individuals with 100% methylation of the FRAXE CpG island were found to have transcription of the gene silenced (13, 14) . Chakrabarti et al. (16) simultaneously reported a candidate gene at the FRAXE fragile site (Ox19, ∼1495 bp transcript) which overlapped with the FMR2 gene but was considerably truncated and possessed a different 3′ end. No expression studies of Ox19 in FRAXE individuals were presented (16) .
Few families co-segregating FRAXE and a mild form of XLMR have been ascertained. This suggests a low incidence of FRAXE MR, difficulty of ascertainment, or both. Screening programs in different candidate populations of mentally impaired boys detected no (4, 17) or only a few new cases of FRAXE MR (18) (19) (20) (21) . Based on these studies, the prevalence of FRAXE was estimated to be ∼4% of FRAXA, or ∼1/50 000 males (22) . However, if FRAXE results in a shift of the distribution of IQ into the mild MR or borderline MR range, leaving a significant overlap between IQ in FRAXE males and normal males, then carriers of FRAXE full mutation may remain unidentified within the community.
*To whom correspondence should be addressed Figure 1 . Comparison of the mRNA and putative protein sequence of FMR2 (13, 14) (lanes 1 and 2) , the FMR2-Ox19 (16) (lanes 3, 4, 6 and 8) transcripts and the genomic DNA (lanes 5, 7, 9 and 10) in the region of the exon 9-intron 9 junction is shown. Boxed regions with translation indicate known exons in the FMR2 transcript (J.G., unpublished data). One extra amino acid with a subsequent stop codon in the FMR2-Ox19 sequence is underlined. The sequence of the very 3′ end of the FMR2-Ox19 transcript diverging from that of FMR2 is highlighted in bold. Two polyadenylation-like signals are underlined (dashed lines). Neither of them, however, fulfils the AAUAAA consensus criterion. The location of the poly(A) tail in the FMR2-Ox19 transcript is indicated with a stretch of 'a's. The location of the two oligonucleotide primers 37 and 38 used for either genomic sequence determination or RT-PCR analysis is indicated by arrows. The present study investigated expression of the FRAXE-associated gene in order to better understand the molecular and clinical pathology of this mild non-specific XLMR. Expression studies for the full-length FMR2 transcript (13, 14) and the truncated Ox19 transcript (16) suggested a possible origin of the truncated FMR2-Ox19 isoform. Additionally, FRAXE family members from seven families co-segregating FRAXE and a mild form of MR were collected and analysed for FMR2 and FMR2-Ox19 expression, FRAXE CpG island methylation and X-inactivation. Expression of FMR2 was extinguished in methylated individuals with expansions of 0.8 kb or greater, while expansions up to 0.7 kb were not methylated. Moreover, two clinically normal individuals were found to have the FRAXE CpG island methylated and, as a consequence, the FMR2 gene transcriptionally silent. Potential implications of these findings for FRAXE genotype-phenotype correlations, diagnosis and screening are discussed.
RESULTS

Transcription of full-length and truncated FMR2 in normal individuals
Full-length (13, 14) and truncated (16) isoforms of the FMR2 gene have been isolated from the region of the FRAXE CpG island. The Northern blot analysis of the Ox19 cDNA showed a 9.5 kb transcript (16) identical in size to that of FMR2 (13) (14) (15) . Sequence comparison between the small 1.5 kb, Ox19 polyadenylated cDNA clone (16) and FMR2 (13, 14) revealed sequence identity in the 5′ ends of the two transcripts. However, starting from position 1367 onwards until reaching the 3′ end (position 1495), the Ox19 transcript diverged from FMR2. In order to demonstrate that the Ox19 transcript was a true isoform of FMR2, genomic sequence was generated around the point of the divergence and RT-PCR performed to demonstrate transcription in different tissues.
The genomic sequence was generated from the YAC D49G8 (13,23) employing a modified IRE-bubble approach (24) (see Materials and Methods) using FMR2-Ox19-specific oligonucleotides 37 and 38 (Fig. 1) . The extra sequence of the FMR2-Ox19 transcript (position 1367-1495) is co-linear with that of genomic DNA ( Fig. 1) . At the point of divergence of the two transcripts, there is an exon-intron boundary in the FMR2 pre-mRNA transcript with a relatively weak 5′ splice donor site [GUGAA/guaag versus consensus A(C)AG/gugag (25)]. As a consequence this weaker 5′ donor splice site may cause alternative splicing of the FMR2 pre-mRNA and so generate the truncated FMR2-Ox19 isoform. The existence of this short isoform was assayed by RT-PCR using primers 37 ( . Among them, the 1.8 kb transcript might correspond to FMR2-Ox19. These transcripts were not detected with several other FMR2 probes from the region of overlap between FMR2 and FMR2-Ox19 (14-16). They may thus represent other cross-reacting or closely related transcripts such as LAF-4 (26) or MLLT2 (27, 28) .
Methylation and X-inactivation studies in FRAXE carriers
Genomic DNA used for methylation and X-inactivation studies was isolated from cultured fibroblast cells. DNA from all FRAXE and control individuals was digested with HindIII alone and then with HindIII and NotI together. The Southern blot was probed with OxE20 (3) . All affected FRAXE males tested showed 100% methylation of the CpG island at the NotI site (Fig. 3 , lanes 3.1, 5, 6.1). In addition, another boy clinically assessed as unaffected with an expansion ∆ = 0.8-4.3 kb (6.2; maternal nephew of individual 6.1, ref. 12) showed 100% methylation of his mosaic FRAXE allele. Methylation was absent however in man 4 (sib of two FRAXE brothers) with a ∆ value of 0.6 kb. The existence of a rare HindIII polymorphism which would mimic FRAXE CCG expansion was excluded by haplotype analysis. The three brothers inherited from their mother the same region of the X chromosome surrounding FRAXE, with different FRAXE CCG expansions (B. Oostra, unpublished results). We reported (9) a similar size unmethylated expanded allele in a carrier female (Table 1, individual 1.2) . Two additional carrier females tested (Table 1 , individuals 3.2 and 7) showed 100% methylation of the expanded allele (∆ = 0.8 kb for individual 3.2 and ∆ = 2.5 kb for 7, respectively).
Southern blot analysis of two phenotypically normal females carrying full mutations (3.2, ∆ = 0.8 kb and 7, ∆ = 2.5 kb) suggested skewed X-inactivation ( Fig. 3 ; intensity of the 2.7 kb HindIII-NotI fragment versus 5.2 kb HindIII product, respectively). Female 1.2 carrying a ∆ = 0.7 kb pre-mutation showed mild mental retardation. To assess the involvement of skewed inactivation to their phenotypes, an X-inactivation study was carried out. X-inactivation was studied in all three females ( Table 1 , individuals 1.2, 3.2 and 7) using a differential methylation assay of HpaII sites in the FMR1 (30) and androgen receptor (AR) (31) genes, respectively. Results are summarized in Table 1 . Only one female (number 7) showed a convincingly skewed pattern of inactivation as determined from the AR assay. The FMR1 assay was not informative as she is homozygous for the FMR1 (CGG) n repeat.
FMR2 expression in FRAXE carriers
Present knowledge about the pattern of expression of the FMR2 gene is derived from Northern blot hybridization on adult (14-16) and fetal (14) tissue mRNA. The suitability of other cellular mRNAs was evaluated for detecting the presence of the FMR2 transcript in cell types usually available in a diagnostic laboratory. Results of this work are summarized in Table 2 . Fibroblasts and cultured chorionic villi cells expressed the highest levels of FMR2, while no expression was detected in lymphoblasts. FMR2 was detected in whole blood cells, hair roots and cultivated amniocytes, however at a very low level. All expression studies were carried out by standard RT-PCR. Usually 35-40 cycles were required to detect the PCR product on an ethidium bromide-stained agarose gel. A number of FMR2-specific primers were used both from the 5′ and 3′ ends (see Materials and Methods). Expression analysis of FMR2 in individuals from FRAXE families was carried out on mRNA isolated from cultured skin fibroblasts. The same fibroblast cultures as for genomic DNA isolation (methylation and X-inactivation study) were used. First strand cDNA was amplified either in a standard PCR or PCR with a fluorescent label (Fig. 4) . Results of the expression study are summarized in Table 1 . All methylated FRAXE chromosomes showed no expression of the FMR2 gene, while all unmethylated FRAXE chromosomes did express the gene. In concordance with the methylation studies, individual 6.2 (assessed as unaffected) did not express the FMR2 gene.
DISCUSSION
The FMR2 gene is associated with the FRAXE CpG island. The three reported transcripts originate from within the CpG island just distal to the FRAXE CCG repeat. While two of the transcripts (13, 14) were identical, the other (16) To date, several (∼19) families co-segregating a mild form of XLMR and FRAXE fragile site have been reported (9) (10) (11) (12) 21, 29) . The behaviour of the FRAXE CCG repeat was found to be similar to that of FRAXA; however, some FRAXE-specific features were noticed. Hamel et al. (11) suggested that there were no FRAXE pre-mutations. Secondly, in two families, affected males had intellectually disabled daughters (11, 12) . Finally, some cytogenetically positive males with FRAXE expansions and full methylation but without intellectual disability have been reported (1,3,9,12,29). To address these anomalies as well as to better characterize the genotype-phenotype relationship in FRAXE MR, we studied a number of individuals from seven FRAXE families. Methylation studies showed that the 0.7 and 0.6 kb expansions of individuals 1.2 and 4, respectively, were not methylated. The latter one would be the largest unmethylated male expansion yet characterized. These cases clearly demonstrate the existence of a FRAXE pre-mutation. In our study, all expansions >0.8 kb were fully methylated (individuals 3.2 and 6.2). The smallest fully methylated expansion reported to date was the one of Hamel et al. (11) of an affected mosaic male with (21) recently reported a large FRAXE and MR co-segregating family with five affected males with expansions ranging from 155 to 815 CCG repeats. While methylation was not observed in a phenotypically normal boy II-4 (pedigree C) with 100 CCG repeats, his mildly affected brothers (II-1, 225 CCGs and II-3, 155 CCGs) were partially methylated (as tested on EcoRI and EagI1 and EagI2 sites). In the absence of the FMR2 expression studies, it was difficult to establish whether these mutations caused reduced or no FMR2 transcription and, as a consequence, borderline to mild mental retardation in their carriers. Further molecular expression studies on these individuals need to be carried out in order to assess the involvement of the FMR2 gene in their phenotype (21) . FMR2 expression analysis on our collection of FRAXE individuals showed correlation between full methylation and silencing of the transcription of the FMR2 gene in all individuals tested (Table 1 ). There were however two males (2.2 and 6.2) who did not express the FMR2 gene, were 100% methylated, but showed normal phenotype. Similar cytogenetically positive, fully methylated but unaffected males have been described by Knight et al. (10) and Murgia et al. (29) ; however, FMR2 expression was not tested. As already speculated (10), the normal phenotype in these individuals might be a result of the clinical variability of the disease, mosaicism or different methylation in different (especially neuronal) tissues. Clinical variability may arise if the severity of the FRAXE MR phenotype is compensated by modifying factors of the genetic background or if the effect of FRAXE full mutation is so mild that intellectually the phenotype can remain within the normal range in some individuals.
Hamel et al. (11) reported two intellectually disabled daughters of two affected brothers who did not express the FRAXE site and inherited a reduced repeat (0.6 and 0.8 kb, respectively) from their fathers. Carbonell et al. (12) described a similar case of father to daughter transmission of a FRAXE phenotype (individual III-6, family 2). We studied an intellectually disabled female originally reported by Mulley et al. (9) (individual III-6, family 1). In this family, both FRAXA and FRAXE were found to segregate. A FRAXE expansion of 0.7 kb was passed to the affected female from her affected grandfather (individual I-1, ref. 9, and 1.1, this study) through her mother who was carrying both FRAXA and FRAXE mutations and was diagnosed as affected. Data obtained from the fibroblasts of the affected daughter showed she had a normal, random X-inactivation, her expanded allele was 50% methylated and she did express the FMR2 gene. Excluding speculations about different methylation and X-inactivation pattern(s) in neural tissue, this female would most likely represent an example of mental impairment due to causes other than FRAXE.
A number of syndromal and non-specific XLMR have been mapped so far (32, 33) . FRAXE-associated MR is the first non-specific MR phenotype where the responsible gene has been cloned (13, 33) . Uncertainty about a genotype-phenotype relationship in FRAXE-associated MR results from the mild phenotypic effect, low incidence and low detection of new FRAXE cases from large candidate population studies (4, (17) (18) (19) (20) (21) . Cloning and identification of the FMR2 gene originating from the FRAXE CpG island enabled molecular definition of a FRAXE phenotype. The mildness of the FRAXE disorder is the main obstacle to its ascertainment. Determination of FRAXE CCG expansion and methylation analysis to indicate the activity status of the FMR2 gene are essential for the characterization of this disorder in families. Extensive psychometric testing with expression studies in FRAXE and related normal controls is necessary to document the magnitude of this mild mental impairment. When faced with requests for prenatal diagnosis, the transmission of FRAXE and sex of the fetus can be determined easily. The problem will be an inability to predict phenotype in males or females with full mutations, a situation which is analogous to the present difficulty for fragile X (FRAXA) syndrome where a female fetus carries the full mutation.
MATERIALS AND METHODS
FRAXE families and patients studied
In this study, we present data from members of seven FRAXE families collected thanks to a wide international collaboration. Altogether we analysed and show here results obtained from six affected FRAXE males, two unaffected sibs of affected FRAXE individuals and three carrier females. As clinical, especially psychometric and familial data have already been or are being presented elsewhere, these are not included. Table 1 gives a summary of individuals examined with references to work describing the clinical data of the corresponding families. Families of individuals 4 and 7 have not been reported yet. Individual 4 has two brothers with an expanded FRAXE CCG repeat (B.A. Oostra, unpublished data), while individual 7 is the mother of a mildly intellectually handicapped male with a FRAXE CCG expansion ∆ = 1.3 kb (G. Turner, unpublished data).
IRE-bubble PCR for sequencing genomic DNA
To generate the genomic sequence around the point of divergence of the FMR2 and FMR2-Ox19 transcripts, the IRE-bubble approach of Munroe et al. (24) has been adopted. Briefly, DNA of the YAC D49G8 was digested with three frequent-cutting enzymes, HaeIII, RsaI and AluI, and ligated to NotI-A bubble anchors. IRE-bubble PCR was carried out on the individual ligation products using the FMR2-Ox19-specific oligonucleotides 37 and 38 in combination with the bubble primer. Thirty to 35 cycles of PCR were performed under the conditions described (24) . Amplification products obtained subsequently were purified by QiaQuick spin columns (Qiagen) and sequenced directly using dye-terminator sequencing chemistry (Perkin Elmer) with the original PCR primers (3.2 pmol per reaction). Sequencing reactions were run and analysed on an ABI373A automated sequencer (Applied Biosystems).
Southern blot analysis
Fibroblast genomic DNA was digested with HindIII alone and HindIII and NotI together at 37_C overnight. Southern blot analysis was performed according to the instructions of the manufacturer of the membranes (Hybond N + ; Amersham). The probe OxE20 (3) was used in methylation studies. After an overnight hybridization at 65_C, the membranes were washed in medium stringency wash (2× SSC; 0.5% SDS at 65_C) and exposed for 2-4 days at -70_C on a radiographic film (DuPont).
X-inactivation studies
For X-inactivation studies, the differential methylation of the HpaII sites in the FMR1 (30) and AR (31) genes was studied. Fibroblast genomic DNA (100 ng) either uncut or pre-digested to completion with HpaII was used. PCR was performed under the conditions described (30,31) using the following primers: FMR1, forward primer 5′-GCGCTCAGCTCCGTTTCGGTTTCA-3′ and reverse 5′-CTCCATCTTCTCTTCAGCCCTGCTA-3′; and AR, forward 5′-TCCAGAATCTGTTCCAGAGCGTGC-3′ and reverse 5′-GCTGTGAAGGTTGCTGTTCCTCAT-3′. Amplification products were analysed on 5% denaturing polyacrylamide gels. Dried gels were exposed to radiographic films (DuPont) for 1-3 days.
Isolation of mRNA and RT-PCR experiments
Cytoplasmic mRNA was isolated either by the guanidinium thiocyanate method (34) followed by oligo(dT) chromatography (Pharmacia), or by using direct mRNA purification on magnetic beads (Dynal). For cultured cells (fibroblasts, lymphoblasts, chorionic villi and amniotic fluid cells), 1×10 5 -5×10 6 cells were processed in a single experiment. Hair roots (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) were collected into the denaturing buffer of the direct mRNA purification kit (Dynal) and homogenized mechanically in a porcelain mortar. To obtain fresh blood, ∼ 100 ml was taken from a finger prick, spun immediately and pellets resuspended in the denaturing buffer (Dynal). Phytohaemaglutinin-stimulated whole blood cells were processed after a 24 h incubation in the same way as fresh blood cells. Approximately 10-200 ng of purified mRNA was random primed for first strand cDNA synthesis using SuperScript II RNase H -reverse transcriptase (BRL). Reverse transcription was carried out for 1 h at 45_C in a water bath. Negative controls where the reverse transcriptase was omitted were run at the same time although the primers were chosen to amplify across large introns. PCR amplifications using either FMR2 gene-specific primers or control esterase D primers were performed on 1/20 of the original reverse transcription reaction. Altogether, 35 cycles of PCR were carrying out (96_C for 30 s; 60_C for 30 s; and 70_C for 1 min) in a final 100 ml volume containing 100 mM Tris-HCl, pH 8.3; 50 mM KCl; 1.5 mM MgCl 2 ; 0.2 mM of each dNTP; 50 pmol of each primer; and 1 U of Taq polymerase (Boehringer). For FMR2 expression studies, the following primers were used: primers 10 5′-GAAAACCCAGTGCAGCCAGTTC-3′ (1358-1379, ref. 13) and 37 5′-TTTCACATGCATCGAGTCCGTT-3′ (Fig. 1) , amplicon 463 bp and/or 376 bp; primers 38 5′-TTAACGGACTC-GATGCATGTGA-3′ (Fig. 1) ; and primer 7 5′-CCCTAAT-GAGACTGAGGAGAGGC-3′ (2143-2122, ref. 13) or 43 5′-CTCAGAGCTGCTCTCCGATTCGC-3′ (1848-1815, ref. 13). Primers 10 and 37 amplify across the exon 5 which was found to be alternatively spliced (13) . As a control, esterase D primers 5′-GGAGCTTCCCCAACTCATAAATGCC-3′ (423-447; GenBank accession no. M13450) and 5′-GCATGATGTCT-GATGTGGTCAGTAA-3′ (875-851, idem), amplicon 452 bp were used (35) . One-third of the PCR product was analysed on 1.5% agarose gels with 0.5 mg/ml of ethidium bromide in 1× TBE.
